OKYO Pharma Limited Dr. Napoleone Ferrara to Serve on the SAB (5128W)
19 August 2020 - 4:00PM
UK Regulatory
TIDMOKYO
RNS Number : 5128W
OKYO Pharma Limited
19 August 2020
19 August 2020
OKYO Pharma Limited
("OKYO" or the "Company")
Appointment of Dr. Napoleone Ferrara to Serve on Its Scientific
Advisory Board
OKYO , the life sciences and biotechnology company, focused on
the discovery and development of novel molecules to treat
inflammatory dry eye diseases and chronic pain, is pleased to
announce that that Dr. Napoleone Ferrara, MD, Professor at the
University of California San Diego Medical Center, has agreed to
serve on its scientific advisory board (SAB).
Dr. Ferrara is a member of The National Academy of Sciences and
has received numerous prestigious awards, including the Lasker
Award and the Breakthrough Prize in Life Sciences. His
research on understanding the role of angiogenesis and vascular
endothelial growth factor (VEGF) in cancer development, led to the
discovery that VEGF is a key mediator of angiogenesis associated
with intraocular neovascular syndromes. This pioneering research
led to the clinical development of a humanized anti-VEGF Fab
(Ranibizumab, Lucentis(R)), which has also been approved as a
therapy for neovascular age-related macular degeneration (AMD),
retinal vein occlusion and diabetic macular edema. Ranibizumab and
other anti-VEGF agents have had a dramatic impact on the
development of therapies for these blinding disorders. When
Lucentis(R) (Ranibizumab) received FDA approval in late June 2006,
the new macular degeneration drug was celebrated as a major medical
breakthrough. Dr. Ferrara's research also led to the development
and approval of humanized anti-VEGF mAbs (Bevacizumab; Avastin(R))
for cancer treatment, with Avastin(R) being one of the bestselling
cancer drugs over the last two decades. Lucentis(R) and Avastin(R)
collectively achieved over $9 billion in sales last year.
Dr. Napoleone Ferrara stated: "I am delighted to join OKYO
Pharma as a member of the SAB. OKYO's focus on the development of
long-acting GPCR agonists to treat dry eye and ocular pain is
scientifically sound and promising. GPCRs are key targets for
pharmacological intervention in a variety of diseases. My expertise
in ocular angiogenesis should complement these efforts and I look
forward to an exciting collaboration".
Willy Simon, Chairman of OKYO said: "We are very excited about
Dr. Napoleone Ferrara's addition to the OKYO team. Very few
scientists have invented two different blockbuster drugs such as
Avastin(R) and Lucentis(R) . Lucentis(R) has become one of the
major blockbuster drugs to treat eye disease and Napoleone's
experience will be a huge value added to Okyo's drug development
effort."
About OKYO
OKYO Pharma Limited (LSE: OKYO) is a life sciences and
biotechnology company admitted to listing on the standard segment
of the Official List of the UK Financial Conduct Authority and to
trading on the Main Market for listed securities of the London
Stock Exchange plc. OKYO is focusing on the discovery and
development of novel molecules to treat inflammatory dry eye
diseases and chronic pain.
Enquiries:
OKYO Pharma Limited Willy Simon +44 (0)20 7495 2379
Optiva Securities Limited
Investors: Robert Emmet + 44 (0)20 3981 4173
Dave Gentry RedChip Companies
dave@redchip.com Inc. +1 407-491-4498
For further information, please visit the Company's website at
www.okyopharma.com.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
BOAPPMBTMTABTBM
(END) Dow Jones Newswires
August 19, 2020 02:00 ET (06:00 GMT)
Okyo Pharma (LSE:OKYO)
Historical Stock Chart
From Apr 2024 to May 2024
Okyo Pharma (LSE:OKYO)
Historical Stock Chart
From May 2023 to May 2024